Global Neuromodulation Market to grow at a CAGR of 8.95% by 2030, Evaluates DelveInsight | Medtronic, Abbott, Boston Scientific Corp, LivaNova, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc

The Key Neuromodulation companies in the market include - Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.

According to DelveInsight's analysis, The rising demand for neuromodulation devices is mainly fueled by the increasing incidence of neurological disorders and a growing patient population affected by chronic pain. Moreover, intensified research and development efforts, along with strategic collaborations among major industry players, are accelerating market expansion. The aging global population also adds to the demand, as elderly individuals are more prone to neurological conditions and persistent pain. Altogether, these factors are expected to drive substantial growth in the neuromodulation devices market throughout the 2024-2030 forecast period.

DelveInsight's "Neuromodulation Market Insights, Competitive Landscape and Market Forecast-2030" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Neuromodulation companies actively working in the market.

To know more about why North America is leading the market growth in the Neuromodulation market, get a snapshot of the report Neuromodulation Market Trends [https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Neuromodulation Overview

Neuromodulation is a therapeutic approach that involves altering nerve activity through targeted delivery of electrical stimulation or pharmaceutical agents to specific areas of the nervous system. It is used to manage chronic pain, movement disorders, epilepsy, and other neurological or psychiatric conditions by modulating the function of neural circuits without permanently damaging them. Common neuromodulation techniques include spinal cord stimulation, deep brain stimulation, and vagus nerve stimulation.

DelveInsight Analysis: The neuromodulation devices market was estimated at USD 5.71 billion in 2023 and is projected to grow at a CAGR of 8.95% from 2024 to 2030, reaching USD 9.56 billion by 2030.

Neuromodulation Market Insights

Geographically, North America is anticipated to lead the neuromodulation devices market throughout the forecast period. This leadership is primarily driven by a rising prevalence of neurological disorders and increased product development initiatives by major industry players. Furthermore, the expanding elderly population in the region significantly supports the market's growth.

To read more about the latest highlights related to Neuromodulation, get a snapshot of the key highlights entailed in the Neuromodulation Market Landscape

https://www.delveinsight.com/report-store/neuromodulation-devices-market [https://www.delveinsight.com/report-store/neuromodulation-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Recent Developments in the Neuromodulation Market Report

*
In March 2025, Sooma Medical received FDA Investigational Device Exemption (IDE) approval for its transcranial direct current stimulation (tDCS) device. This clearance enables the company to initiate a pivotal clinical trial. Headquartered in Helsinki, Finland, Sooma developed the portable neuromodulation device specifically for the treatment of depression.

*
In January 2024, Boston Scientific Corporation revealed it has signed a definitive agreement to acquire Axonics, Inc. for USD 3.4 billion. This acquisition enhances Boston Scientific's neurostimulation device portfolio by incorporating Axonics' advanced sacral neuromodulation technologies.

*
In March 2022, Bioventus announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation StimRouter Registered Neuromodulation System, designed to treat chronic pain. The StimRouter system is a minimally invasive device that includes a slim implanted lead with a conductive electrode, an external electric field conductor (E-EFC), and the StimRouter Plus Mobile App.

*
In March 2021, Helius Medical received approval from the US FDA for its Portable Neuromodulation Stimulator, intended for the short-term treatment of gait impairment associated with multiple sclerosis.

*
In January 2021, Boston Scientific Corporation obtained FDA approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System, designed to manage symptoms in individuals with advanced Parkinson's disease.

*
Thus, owing to such developments in the market, rapid growth will be observed in the Neuromodulation market during the forecast period

Key Players in the Neuromodulation Market

Some of the key market players operating in the Neuromodulation market include- Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.

Which MedTech key players in the Neuromodulation market are set to emerge as the trendsetter explore @ Key Neuromodulation Companies [https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Analysis on the Neuromodulation Market Landscape

The increasing occurrence of neurological disorders is expected to play a major role in accelerating market growth, largely due to the extensive use of neuromodulation devices in their treatment. As reported by the World Health Organization (WHO) in March 2024, migraines and other headache-related conditions impacted 3.1 billion individuals worldwide in 2021.

Recent innovations in spinal cord stimulators, including features like rechargeable batteries and wireless remote technology, are driving growth in this segment. For example, in December 2022, Abbott Laboratories introduced the Eterna Trademark spinal cord stimulation (SCS) system for managing chronic pain. This system utilizes Abbott's proprietary BurstDR stimulation, which replicates the brain's natural firing patterns to deliver enhanced pain relief. Additionally, the device supports wireless charging as seldom as five times annually, offering a more convenient user experience. These advancements by leading companies are expected to fuel market expansion.

Scope of the Neuromodulation Market Report

*
Coverage: Global

*
Study Period: 2021-2030

*
Neuromodulation Market Segmentation By Type: Invasive and Non-Invasive

*
Neuromodulation Market Segmentation By Product: Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others

*
Neuromodulation Market Segmentation By Application Type: Pain Management, Neurological Disorder, Respiratory Disorders, and Others

*
Neuromodulation Market Segmentation By End-User: Hospitals, Specialty Clinics, and Others

*
Neuromodulation Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

*
Key Neuromodulation Companies: Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others

*
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Neuromodulation market will grow by 2030? Click to get a snapshot of the Neuromodulation Market Analysis [https://www.delveinsight.com/sample-request/neuromodulation-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Neuromodulation Market Report Introduction

2

Neuromodulation Market Executive summary

3

Regulatory and Patent Analysis

4

Neuromodulation Market Key Factors Analysis

5

Porter's Five Forces Analysis

6

COVID-19 Impact Analysis on Neuromodulation Market

7

Neuromodulation Market Layout

8

Global Company Share Analysis - Key 3-5 Companies

9

Company and Product Profiles

10

Project Approach

11

Neuromodulation Market Drivers

12

Neuromodulation Market Barriers

13

About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=global-neuromodulation-market-to-grow-at-a-cagr-of-895-by-2030-evaluates-delveinsight-medtronic-abbott-boston-scientific-corp-livanova-neurosigma-inc-nevro-corp-synapse-biomedical-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.